Introduction
============

Chronic obstructive pulmonary disease (COPD) is characterized by a chronic progressive deterioration in lung function and commonly results in dyspnea on activity, and impaired health status. In addition, periodic worsenings of the disease, referred to as exacerbations, occur with increasing frequency as the disease advances and are felt to adversely affect health status and to hasten the already accelerated decline in lung function seen in COPD patients ([@b51-copd-2-157]; [@b30-copd-2-157]; [@b20-copd-2-157]). COPD guidelines currently advocate aggressive smoking cessation, certain non-pharmacologic management strategies such as exercise and pulmonary rehabilitation, and a stepped approach to pharmacotherapy. The latter includes initial treatment with short-acting bronchodilators, progressing to the addition of long-acting anticholinergic bronchodilators or long-acting beta~2~-adrenergic bronchodilators, or both, for patients with more advanced airway obstruction and persisting symptoms.

In contrast to current asthma guidelines, where inhaled corticosteroids (ICS) are central to therapy of all patients with regular symptoms ([@b24-copd-2-157]), current COPD-guidelines are more cautious regarding the role of ICS, recommending their use only in symptomatic COPD patients with a documented spirometric or clinical response to ICS, or in those patients with an FEV~1~ \<50% predicted and who suffer repeated exacerbations requiring antibiotics and/or therapy with oral corticosteroids ([@b46-copd-2-157]; [@b44-copd-2-157]; [@b38-copd-2-157]). Despite what guidelines recommend, ICS are commonly prescribed for patients with COPD, while the merits of this practice continue to be debated ([@b3-copd-2-157]; [@b10-copd-2-157]; [@b53-copd-2-157]). This empiric practice may have some justification, as it has been demonstrated that withdrawal of ICS from patients with COPD is associated with an increase in exacerbation rates and worsening health status, as well as a deterioration in lung function and increased exertional breathlessness ([@b40-copd-2-157]; [@b56-copd-2-157]; [@b61-copd-2-157]). A few studies ([@b45-copd-2-157]; [@b60-copd-2-157]; [@b9-copd-2-157]; [@b33-copd-2-157]; [@b47-copd-2-157]) have suggested a beneficial effect from ICS at reducing the number of COPD exacerbations for patients with advanced disease (FEV~1~ \<50% predicted), and a meta-analysis of such trials reported a 30% reduction in COPD exacerbations with ICS ([@b2-copd-2-157]). However, other randomized clinical trials have not shown benefit from ICS in COPD ([@b7-copd-2-157]; [@b11-copd-2-157]; [@b54-copd-2-157]). Recently, the methodology of statistical analysis used in many of these trials has been questioned ([@b53-copd-2-157]). According to this line of reasoning, conclusions concerning the effect of ICS on the frequency of COPD exacerbations should be considered flawed whenever the overall rate of COPD exacerbations has been calculated by treating all patients equally and simply averaging individual patient exacerbation rates. This so-called unweighted approach is overly sensitive to individual follow-up times which usually vary significantly within a given trial, and can therefore lead to a biased estimate of exacerbation rate ratios ([@b53-copd-2-157]).

While long-acting beta~2~-adrenergics appear to be effective when added to inhaled steroids for many outcomes in patients with advanced COPD ([@b36-copd-2-157]; [@b11-copd-2-157], [@b12-copd-2-157], [@b13-copd-2-157]), there are no data yet available assessing the efficacy of adding tiotropium, a long-acting anticholinergic inhaled bronchodilator for once-daily inhalation ([@b34-copd-2-157]; [@b19-copd-2-157]; [@b32-copd-2-157]; [@b26-copd-2-157]) to ICS alone in COPD patients. At least in theory, if ICS could reduce airway inflammation, peripheral mucus plugging and airway wall compliance might be expected to improve, leading to a greater response to bronchodilator therapy. Whether differential effects might also be observed between different classes of bronchodilators is also unknown.

Donohue et al reported results from a placebo-controlled study over 6 months comparing tiotropium and the long-acting beta~2~-adrenergic, salmeterol, in patients with moderately advanced COPD ([@b22-copd-2-157], [@b21-copd-2-157]). Tiotropium provided sustained and superior improvement in 12-hour lung function compared to salmeterol. When the data from this trial were combined with a similar 6-month trial in COPD patients for the analysis of patient-centred outcomes, additional benefits for tiotropium over salmeterol were indicated in symptoms, health status and the frequency of COPD exacerbations ([@b8-copd-2-157]). In these latter two studies, 66% of the patients enrolled had been prescribed ICS on a regular basis. The completion of these two placebo-controlled 6-month clinical studies has presented the opportunity to retrospectively analyze the relative efficacy of tiotropium and salmeterol as a function of the concomitant use of ICS in patients with moderately advanced COPD.

Patients and methods
====================

Study design
------------

This is a retrospective analysis of the pooled results of two similar 6-months, randomized, double-blind, double-dummy, placebo-controlled, parallel group studies of inhaled tiotropium bromide (18 μg once daily via the HandiHaler®) and salmeterol (50 μg twice daily via a CFC metered dose inhaler) in the treatment of patients with COPD (study codes 205.130 and 205.137). The only difference in the two studies was the duration of serial spirometry in the clinic (12 hours in one study, 3 hours in the second) ([@b8-copd-2-157]; [@b22-copd-2-157], [@b23-copd-2-157]). The studies were conducted in 18 countries. All patients provided written consent and the studies were approved by the respective ethics committees and institutional review boards.

The study design has previously been described ([@b8-copd-2-157]; [@b22-copd-2-157], [@b23-copd-2-157]). In brief, following an initial screening to assess eligibility, patients had entered a 2-week baseline period. Patients who successfully completed this phase were randomized into the double-blind portion of the study during which they received tiotropium, salmeterol or placebo for a period of 24 weeks. The drugs were administered in a double-dummy design with tiotropium or placebo inhalation capsules taken once daily in the morning and salmeterol or placebo inhalation aerosol taken twice daily (every 12 hours). Clinic visits were scheduled after 2, 8, 16, and 24 weeks following randomization.

Study patients
--------------

The main inclusion criteria were: age ≥40 years, a diagnosis of COPD with pre-bronchodilator FEV~1~ at screening visit of ≤60% predicted (calculated according to European Commission for Steel and Coal criteria and using predicted values from Morris) ([@b37-copd-2-157]; [@b49-copd-2-157]) and screening FEV~1~/FVC \<0.70. Patients were required to have a smoking history of ≥10 pack-years, and be able to perform all study related tests including acceptable pulmonary function tests and maintenance of daily diary card records. The main exclusion criteria were clinically significant diseases other than COPD which, in the opinion of the investigator, had the potential to impact on the patient's ability to participate in the study, as well as known symptomatic prostatic hypertrophy, bladder neck obstruction, or narrow-angle glaucoma. Additionally, patients with a history of asthma, allergic rhinitis, or atopy or who had a total blood eosinophil count of ≥600/μL, patients requiring use of supplemental oxygen therapy for more than 1 hour per day, a history of life-threatening pulmonary obstruction, a history of cystic fibrosis or bronchiectasis, thoracotomy with pulmonary resection, upper respiratory infection in the 6 weeks prior to the screening visit or during the run-in period were also excluded.

Treatment with long-acting beta~2~-adrenergics and anticholinergics, other than study treatment, was discontinued at randomization. Patients were allowed to continue treatment with stable doses of ICS, theophyllines, and short-acting beta~2~-adrenergic medication as scheduled prior to the study. Patients using oral corticosteroids within or 6 weeks prior to the study were not included in the analysis.

Efficacy evaluations
--------------------

Pulmonary function testing was conducted prior to the start of therapy at 60 and 10 minutes pre-dose at the randomization visit and at 30 minutes, 60 minutes, 2, and 3 hours post-dosing. As only one study collected spirometry after 3 hours during clinic visits, only spirometry up to 3 hours post-dosing has been considered for the present analysis. Pulmonary function tests were repeated at the same time intervals after 2, 8, 16, and 24 weeks of therapy. The bronchodilator efficacy of tiotropium and salmeterol was primarily determined by trough FEV~1~ and FVC response, which was defined as the change from baseline at the end of the dosing interval, approximately 24 hours post drug administration for tiotropium and approximately 12 hours post drug administration for salmeterol. Baseline values were the mean of the two pre-treatment values measured in the morning of the randomization visit prior to administration of the first dose of study medication. Other spirometric parameters analyzed included the peak response and AUC~0--3~ response.

Patient and investigator administered questionnaires, including the St. George's Respiratory Questionnaire (SGRQ) ([@b29-copd-2-157]) and Mahler's Dyspnea Index ([@b35-copd-2-157]), were administered at baseline and after 8, 16, and 24 weeks of therapy. Requirement for as-needed salbutamol (albuterol) was monitored throughout the study period. Exacerbations were reported as adverse events and were defined as a complex of respiratory symptoms (ie, at least one of cough, sputum, dyspnea, wheeze, chest discomfort) lasting at least 3 days and usually associated with a therapeutic intervention.

Statistical analysis
--------------------

Data from both studies were pooled for analysis. Patients receiving ICS at the time of randomization were separately analyzed from those patients without concurrent ICS treatment. For the spirometry measurements, SGRQ total score and TDI focal score, analysis of covariance was performed with the baseline as a covariate. In order to include the same patients at each time point in the 3 hour spirometry summaries, missing values were estimated using other values recorded for the patient on that test day. Linear interpolation between the two adjacent measurements was used to estimate random, middle, and missing spirometry measurements. For values at the end of the profiles that were missing because rescue medication was taken, the minimum observed FEV~1~ value on that test day was used as the estimate. The last available value was used as the estimate for data that were missing for other reasons.

For the SGRQ, missing individual questions were imputed according to the guidelines established by the questionnaire developer. Data from missing SGRQ questionnaires and TDI questions were imputed using last observation carried forward, unless the patient discontinued due to worsening of COPD, in which case the least favorable observation was carried forward. The numbers of exacerbations over the 6 months period were compared across treatment groups using Poisson regression with logarithm of exposure as offset and correction for overdispersion as recommended by [@b53-copd-2-157].

Unless otherwise specified, data are presented as means ± standard error. Statistical significance was considered at p \< 0.05.

Results
=======

A total 796 of 1207 patients (66%) in the two trials were concurrently treated with ICS. Demographic data and baseline characteristics for the treatment groups were comparable (Tables [1a](#t1-copd-2-157){ref-type="table"}, b). For patients concurrently treated with ICS, mean pre-bronchodilator FEV~1~ values were 39%, 38%, and 40% of predicted in the tiotropium, salmeterol, and placebo groups respectively. In general, at baseline, the group of patients taking ICS had slightly more airway obstruction and poorer health status scores than patients not on ICS (p \< 0.05). The median daily doses and dose ranges of ICS used by the majority of these patients for at least 3 months prior to the study are shown in Table [2](#t2-copd-2-157){ref-type="table"}. Fluticasone was the most commonly used ICS (approximately 35%--40% in each group) with a median daily dose of 1000 μg. The apparent large dose ranges observed reflect extreme ICS dosing by one or two patients in each treatment group. Twenty-one patients from the original data sets, not taking ICS, but receiving regular treatment with oral corticosteroids, were excluded from the analysis. There were 168 patients concurrently taking ICS who were prematurely withdrawn from the studies for various reasons. Significantly fewer patients taking ICS withdrew in the tiotropium (17%) and salmeterol (19%) groups compared with placebo (27%) (p \< 0.05). Similarly, 68 patients not taking ICS treatment did not complete the studies. Of those not taking ICS, significantly fewer patients in the tiotropium group (11%) withdrew compared with those in the placebo group (23%) (p \< 0.05). The percentages of patients who withdrew in the salmeterol group (18%) were not significantly different from placebo. Overall, adverse events leading to discontinuation from the studies occurred in 9%, 16%, and 18% of ICS patients, and in 4%, 13%, and 15% of patients not using ICS, but these differences were not statistically significant. The main adverse event causing early withdrawal was worsening of COPD (ICS: 6% tiotropium, 12% salmeterol, 12% placebo; non-ICS groups: 3%, 6%, and 10%, respectively).

Lung function responses
-----------------------

### Patients treated with ICS

Compared with placebo, patients in both the tiotropium and salmeterol groups concurrently treated with ICS achieved statistically significant improvements in FEV~1~ and FVC (trough, peak and AUC~0--3~ hours) throughout the study (p ≤ 0.001, all comparisons at day 15, 57, 113, and 169) (Figure [1](#f1a-copd-2-157){ref-type="fig"} and Table [3a](#t3-copd-2-157){ref-type="table"}). After 169 days of treatment, the mean ± SE improvement above placebo in trough FEV~1~ was 110 ± 20 mL for tiotropium (p \< 0.001) and 80 ± 20 mL for salmeterol (p \< 0.001) (Table [3a](#t3-copd-2-157){ref-type="table"}). The numerical difference (10--30 mL) in trough FEV~1~ between tiotropium and salmeterol was not significant at 6 months (p = 0.11 tiotropium vs salmeterol). Tiotropium was superior in improving trough FVC of patients using ICS from day 57 to 169 (p \< 0.05, tiotropium vs salmeterol), and differences between active treatments were also statistically significant in favor of tiotropium for peak FEV~1~ and FVC at the first dose and at all subsequent visits (p \< 0.05, tiotropium vs salmeterol). In addition, FEV~1~ AUC~0--3~, as well as FVC AUC~0--3~ were consistently statistically significant in favor of tiotropium (p \< 0.01, tiotropium vs salmeterol) from day 15 to day 169.

### Patients not treated with ICS

In those patients not taking ICS, the patterns of spirometric response according to treatment group were similar to those observed with the ICS group (Figure [2](#f2a-copd-2-157){ref-type="fig"} and Table [4a](#t4-copd-2-157){ref-type="table"}). However, because of the smaller sample size (n = 360) relative to the ICS treated group (n = 796), there was insufficient power to detect statistically significant differences between bronchodilators in this group of patients.

Dyspnea responses
-----------------

### Patients treated with ICS

The mean baseline dyspnea index (BDI) of the patients using ICS was 6.2--6.3 in the various treatment groups, reflecting a moderate level of dyspnea for all patients at the start of the study (Table [1a](#t1-copd-2-157){ref-type="table"}). Compared with placebo, ICS patients treated with tiotropium demonstrated a clinically and statistically significant improvement in TDI focal score throughout the study (p \< 0.01 at all time points). Patients treated with salmeterol also achieved a statistically significant improvement in TDI focal score compared with placebo, only after 8 weeks of therapy (p \< 0.01), but failed to sustain this improvement compared with placebo at 16 and 24 weeks. The difference in TDI focal score between the tiotropium and salmeterol groups was not statistically significant. However, only in patients treated with tiotropium did the improvement in TDI reach the minimal clinically important difference of 1 unit after 169 days of treatment (Table [3a](#t3-copd-2-157){ref-type="table"}).

Patients not treated with ICS
-----------------------------

In patients not being treated with ICS, the mean improvement in dyspnea as measured by the TDI focal score after 169 days of treatment was above the minimal clinically important difference of 1.0 for both tiotropium and salmeterol, but only in patients receiving tiotropium was this difference statistically significantly different from placebo (Table [4a](#t4-copd-2-157){ref-type="table"}).

Health status responses
-----------------------

### Patients treated with ICS

Health status, as quantified by the change in SGRQ total score after 169 days on treatment, improved significantly in patients on ICS treated with tiotropium (−3.27 ± 1.22 vs placebo; p \< 0.01), but not in patients receiving salmeterol (−1.12 ± 1.21; p \> 0.05 vs placebo) (Table [4a](#t4-copd-2-157){ref-type="table"}). Although only patients receiving tiotropium experienced a statistically significant improvement in SGRQ vs placebo, there was no significant difference in SGRQ total score after 6 months between the tiotropium and salmeterol groups. When the change in SGRQ total score from baseline is considered, only the tiotropium group showed an improvement equal to or greater than the accepted minimally important clinical difference of 4 units (Figure [3](#f3-copd-2-157){ref-type="fig"}).

### Patients not treated with ICS

In patients without concurrent ICS treatment, the improvement in health status achieved by active study drugs after 169 days of treatment did not reach the level of significance (Table [4a](#t4-copd-2-157){ref-type="table"}).

Exacerbations
-------------

### Patients treated with ICS

In patients concurrently treated with ICS there was a trend towards reduced exacerbation frequency and number of exacerbation days experienced by the tiotropium and salmeterol groups compared with the placebo group (Table [3b](#t3-copd-2-157){ref-type="table"}). Fewer patients in both the tiotropium and salmeterol groups experienced 1 or more exacerbations during the 6 months treatment period compared with placebo (40% receiving tiotropium or salmeterol, 45% receiving placebo), although the differences were not statistically significant (Table [3b](#t3-copd-2-157){ref-type="table"}).

### Patients not treated with ICS

In patients not receiving concurrent treatment with ICS (Table [4b](#t4-copd-2-157){ref-type="table"}), only tiotropium use was associated with a significant reduction in the number of COPD exacerbations (p \< 0.05) and in the number of exacerbation days (p \< 0.05). The reduction in the proportion of patients experiencing an exacerbation of COPD approached statistical significance (p = 0.08). Salmeterol use was associated with a significant numerical reduction in exacerbations in this subgroup of patients (p = 0.81).

Safety
------

A safety summary of the two studies was published previously ([@b8-copd-2-157]). Both active treatments were well tolerated, with dry mouth the predominant adverse event reported in 8% of patients receiving tiotropium (salmeterol and placebo 2%, each).

Discussion
==========

A pooled analysis from two studies comparing the long-acting anticholinergic tiotropium to the long-acting beta~2~-adrenergic salmeterol in patients with COPD had previously demonstrated a sustained and superior improvement in lung function with tiotropium 18 μg once-daily compared to salmeterol 50 μg twice-daily regardless of concurrent use of ICS ([@b8-copd-2-157]; [@b22-copd-2-157], [@b23-copd-2-157]). In these two studies, 66% of the patients enrolled had been prescribed ICS on a regular basis, providing the opportunity to retrospectively analyze the relative efficacy of tiotropium and salmeterol as a function of the concomitant use of ICS in patients with moderately advanced COPD.

In patients with moderate-to-severe COPD, our present post-hoc analysis demonstrated superior spirometric responses with tiotropium plus ICS compared to salmeterol plus ICS. Both long-acting bronchodilators demonstrated an improvement in lung function, similar to that observed in the original study populations which included patients with and without ICS, and it is noteworthy that in the present sub-group analysis ICS did not appear to protect against the loss of bronchodilator activity over time that was observed to occur for salmeterol in the original data set ([@b22-copd-2-157], [@b21-copd-2-157]). The findings of these two studies comparing tiotropium, salmeterol, and placebo are consistent with many published studies addressing efficacy of bronchodilators in COPD and add weight to the modern concept that COPD is not necessarily a disease with fixed airflow obstruction, but rather that COPD patients often demonstrate considerable bronchodilator response ([@b39-copd-2-157]; [@b15-copd-2-157]; [@b41-copd-2-157], [@b42-copd-2-157], [@b43-copd-2-157]; [@b55-copd-2-157]). Regarding dyspnea and health status in patients concurrently using ICS, in the current analysis, only those receiving tiotropium showed statistically significant improvement after 24 weeks on treatment, and only in the tiotropium group did these improvements reach accepted levels of clinical importance.

In the original study population there was a relatively low number of exacerbations, and in the current subgroup analysis only 27% of placebo patients without ICS and 45% of placebo patients concurrently treated with ICS experienced any exacerbation during the 6-month observation period. Although in the original study patients using ICS had experienced more exacerbations (1.76 exacerbations per patient per year in the placebo group) than patients without ICS (1.0 exacerbations/patient/year, placebo), because patients were not randomized to ICS or non-ICS groups, it should be stressed that a comparison of these sub-groups is of limited value. This apparent difference in exacerbation rates according to concurrent ICS use may simply indicate that the patients' physicians had prescribed ICS for those patients they felt to have the most unstable COPD. The trend towards a reduced number of exacerbations experienced by the patients of this subgroup analysis receiving tiotropium (−23%) and salmeterol (−17%) did not reach statistical significance, but the magnitude of effect resembled that observed in the original study population ([@b8-copd-2-157]). A recently reported prospective trial comparing the addition of combined salmeterol/fluticasone, salmeterol alone, or placebo with COPD patients receiving tiotropium was also unable to demonstrate a statistically significant difference in COPD exacerbation frequency amongst the treatment groups, but compared with placebo, the group treated with tiotropium plus salmeterol/fluticasone had significantly fewer hospitalizations ([@b1-copd-2-157]). Recent prospective studies have observed a positive impact of adding an ICS to a long-acting beta~2~-adrenergic on spirometric response, health status, and COPD exacerbations ([@b11-copd-2-157], [@b13-copd-2-157]; [@b36-copd-2-157]; [@b54-copd-2-157]). The effect of this treatment strategy on mortality in COPD has also been recently studied, but although an absolute reduction in mortality of 2.6% was observed, with the combination therapy, this did not achieve statistical significance ([@b13-copd-2-157]). Prospective trials designed to assess the effect of adding an ICS to an anticholinergic bronchodilator alone have not been published.

The role of ICS without long-acting bronchodilators in the treatment of COPD continues to be a matter of debate. Many patients with COPD appear to be steroid-resistant based on in vitro studies ([@b4-copd-2-157], [@b5-copd-2-157]; [@b18-copd-2-157]). However, because clinical trials usually report only mean treatment responses, it could be postulated that ICS are beneficial in COPD, but only for certain sub-sets of patients who are not otherwise identified in clinical trials. For example, ICS may have beneficial effects by modulating inflammation driven by eosinophils when present ([@b48-copd-2-157]; [@b31-copd-2-157]), or mast cells ([@b28-copd-2-157]). ICS have also been shown to reduce some of the systemic markers of inflammation in COPD patients ([@b52-copd-2-157]) and to modulate oxidative damage in COPD ([@b50-copd-2-157]).

The parasympathetic nervous system is felt to be the main determinant of airway smooth muscle tone ([@b23-copd-2-157]; [@b17-copd-2-157]; [@b4-copd-2-157]; [@b26-copd-2-157]) and there is evidence that cholinergic tone is increased in COPD ([@b27-copd-2-157]; [@b25-copd-2-157]). It has therefore been suggested that COPD could be more effectively treated with anticholinergic drugs than by sympathomimetics ([@b4-copd-2-157]; [@b26-copd-2-157]). Clinical data about the co-administration of tiotropium with inhaled long-acting beta~2~-adrenergics is also beginning to emerge and it would seem that such additivity does indeed occur ([@b14-copd-2-157], [@b16-copd-2-157]; [@b55-copd-2-157]; [@b58-copd-2-157], [@b59-copd-2-157], [@b60-copd-2-157]).

In summary, the present post-hoc analysis of two large-scale trials, comparing the M~3~ receptor antagonist tiotropium and the long-acting beta~2~-adrenergic salmeterol to placebo in COPD subgroups with or without concurrent treatment with ICS, confirms that both, tiotropium and salmeterol are effective bronchodilators. Clinically important endpoints such as dyspnea, health status and frequency of exacerbations were also observed and were superior with tiotropium compared to salmeterol, regardless of concomitant ICS use. While the direct effect of ICS on COPD outcomes was not studied in this post-hoc analysis, we conclude that concurrent use of ICS neither augmented nor impeded the relative efficacy of the two bronchodilators tested.
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###### 

Patient characteristics at baseline

  --------------------------------------------------------------------- ---------------- ---------------- -------------
  \(a\) Patient characteristics (ICS users) at baseline (mean \[SD\])                                     
                                                                                                          
                                                                        **Tiotropium**   **Salmeterol**   **Placebo**
                                                                                                          
  N                                                                     259              278              259
  Mean age (yrs)                                                        64 (8)           64 (8)           65 (8)
  Male (%)                                                              79               76               78
  Current smokers (%)                                                   41               29               36
  Smoking history (pack years)                                          43 (23)          44 (24)          41 (23)
  FEV~1~ (L)                                                            1.08 (0.37)      1.03 (0.39)      1.09 (0.40)
  FEV~1~ (%predicted)[a](#tfn1-copd-2-157){ref-type="table-fn"}         39 (12)          38 (13)          40 (13)
  FVC (L)                                                               2.53 (0.71)      2.51 (0.78)      2.60 (0.80)
  BDI (0--12)                                                           6.3 (2.2)        6.2 (2.3)        6.3 (2.2)
  SGRQ (Total) (0--100)                                                 47 (17)          47 (17)          46 (16)
  --------------------------------------------------------------------- ---------------- ---------------- -------------

([@b37-copd-2-157]).

([@b37-copd-2-157]).

###### 

Median daily dose and ranges of ICS in treatment groups for patients concurrently taking ICS

  **ICS type and median dose (μg/day)**   **Tiotropium**   **Salmeterol**   **Placebo**                     
  --------------------------------------- ---------------- ---------------- ------------- ----------- ----- -----------
  fluticasone (1000)                      41%              100--1500        36%           220--2000   44%   100--2000
  budesonide (800)                        33%              160--2400        35%           50--2400    29%   400--1800
  beclomethasone (1000)                   23%              200--1600        25%           100--2000   22%   100--2250

Note: Percentages do not add up to 100% because of the use of other ICS (flunisolide, triamcinolone) by 2%--3% of patients in each treatment group.

###### 

Outcomes in patients using ICS (tiotropium: n = 259; salmeterol: n = 278; placebo: n = 259)

  --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------------------------------------------
  \(a\) Treatment response (spirometry, TDI, and SGRQ score) after 169 days                                                                                                                                                                                                       
                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                **Tiotropium vs placebo**                                                                         **Salmeterol vs placebo**
                                                                                                                                                                                                                                                                                  
  FEV~1~                                                                      Trough                                                                                            110 ± 20[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}                                             80 ± 20[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}
  Peak                                                                        220 ± 30[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}[†](#tfn5-copd-2-157){ref-type="table-fn"}   150 ± 30[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}                                             
  AUC ~0--3~                                                                  190 ± 20[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}[†](#tfn5-copd-2-157){ref-type="table-fn"}   130 ± 20[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}                                             
  FVC                                                                         Trough                                                                                            220 ± 40[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}[†](#tfn5-copd-2-157){ref-type="table-fn"}   130 ± 40[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}
  Peak                                                                        400 ± 40[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}[†](#tfn5-copd-2-157){ref-type="table-fn"}   220 ± 40[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}                                             
  AUC~0--3~                                                                   370 ± 40[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}[†](#tfn5-copd-2-157){ref-type="table-fn"}   230 ± 40[\*\*](#tfn4-copd-2-157){ref-type="table-fn"}                                             
  TDI focal score                                                                                                                                                               1.03 ± 0.4[\*](#tfn3-copd-2-157){ref-type="table-fn"}                                             0.57 ± 0.4
  SGRQ total score                                                                                                                                                              −3.27 ± 1.2[\*](#tfn3-copd-2-157){ref-type="table-fn"}                                            −1.12 ± 1.2
  --------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------- -------------------------------------------------------

p \< 0.05,

p \< 0.001 vs placebo;

p \< 0.05, tiotropium vs salmeterol.

p = 0.047,

p = 0.135 vs placebo.

###### 

Outcomes in patients not using ICS (tiotropium: n = 135; salmeterol: n = 120; placebo: n = 135)

  --------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------
  \(a\) Treatment response (spirometry, TDI, and SGRQ score) after 169 days                                                                                                                                                           
                                                                                                                                                                                                                                      
                                                                                                                                                                              **Tiotropium vs placebo**                               **Salmeterol vs placebo**
                                                                                                                                                                                                                                      
  FEV~1~                                                                      Trough                                                                                          150 ± 30[\*](#tfn8-copd-2-157){ref-type="table-fn"}     110 ± 30[\*](#tfn8-copd-2-157){ref-type="table-fn"}
  Peak                                                                        220 ± 30[\*](#tfn8-copd-2-157){ref-type="table-fn"}[†](#tfn9-copd-2-157){ref-type="table-fn"}   150 ± 30[\*](#tfn8-copd-2-157){ref-type="table-fn"}     
  AUC ~0--3~                                                                  220 ± 30[\*](#tfn8-copd-2-157){ref-type="table-fn"}[†](#tfn9-copd-2-157){ref-type="table-fn"}   150 ± 30[\*](#tfn8-copd-2-157){ref-type="table-fn"}     
  FVC                                                                         Trough                                                                                          190 ± 50[\*](#tfn8-copd-2-157){ref-type="table-fn"}     130 ± 50[\*](#tfn8-copd-2-157){ref-type="table-fn"}
  Peak                                                                        300 ± 60[\*](#tfn8-copd-2-157){ref-type="table-fn"}                                             200 ± 60[\*](#tfn8-copd-2-157){ref-type="table-fn"}     
  AUC ~0--3~                                                                  290 ± 50[\*](#tfn8-copd-2-157){ref-type="table-fn"}                                             200 ± 50[\*](#tfn8-copd-2-157){ref-type="table-fn"}     
  TDI focal score                                                                                                                                                             1.35 ± 0.5[\*](#tfn8-copd-2-157){ref-type="table-fn"}   1.02 ± 0.55
  SGRQ total score                                                                                                                                                            −2.05 ± 1.7                                             −1.66 ± 1.8
  --------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------- ------------------------------------------------------- -----------------------------------------------------

p \< 0.05 vs placebo;

p \< 0.05, tiotropium vs salmeterol.

p \< 0.05 vs placebo.
